Skip to main content

Biden’s move on vaccine patents represents blow for the second-biggest spender on Washington lobbying

The Biden administration’s Wednesday decision to support waiving intellectual-property protections for COVID-19 vaccines counts as a significant disappointment for drugmakers, who rank among the biggest spenders on Washington lobbying.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.